Allergan Aesthetics, an AbbVie company, announces the national launch of Juvéderm VOLUX XC. The hyaluronic acid (HA) filler is now available at aesthetic practices for consumers over the age of 21 with moderate to severe loss of jawline definition.

“With 40% of aesthetically aware consumers considering treatment in the next year to their jawline or jowls with dermal filler, Allergan Aesthetics is excited to address this need by offering Juvéderm VOLUX XC, a specifically designed and well-researched solution,” says Carrie Strom, president of Global Allergan Aesthetics and senior vice president of AbbVie. “As the category leader, we continue to innovate by providing aesthetic specialists and patients the broadest portfolio of differentiated fillers.”

“Many different types of patients can benefit from Juvéderm VOLUX XC whether you want to address the appearance of jowls or the contour of the jawline,” adds Sachin Shridharani, MD, board-certified plastic surgeon. “With the addition of this new dermal filler to the Juvéderm Collection, I can create a smooth, natural-looking, and long-lasting contour that lasts up to 12 months with optimal treatment.”

Juvéderm VOLUX XC is the latest line in the Juvéderm Collection, and offers a minimally invasive, non-surgical treatment option with minimal downtime, according to company officials. In the Juvéderm VOLUX XC clinical trial, patients reported high satisfaction with the results of their treatment, Juvéderm officials add. 

“The shape of the jawline has a profound effect on an individual’s appearance, which makes treating this area challenging and requires the practitioner to have advanced skills and precision,” says David Shafer, MD, a double board-certified plastic surgeon and Allergan Medical Institute (AMI) trainer. “With the approval of Juvéderm VOLUX XC, the AMI curriculum has expanded to include in-depth training, robust clinical trial data, and resources backed by science to ensure that providers have the proper knowledge and technique required to safely treat appropriate patients to meet their aesthetic goals,” Shafer adds.